Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P

Open Access

Peer-reviewed

Research Article

Abid R. Mattoo,

Affiliation Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Ira Pastan,

Affiliation Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
David FitzGerald

* E-mail: fitzgerd@helix.nih.gov

Affiliation Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯

Reader Comments (0)

Protein synthesis
Is the Subject Area "Protein synthesis" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Toxic agents
Is the Subject Area "Toxic agents" applicable to this article?

Thanks for your feedback.
Toxins
Is the Subject Area "Toxins" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Bacterial toxins
Is the Subject Area "Bacterial toxins" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Pancreatic cancer
Is the Subject Area "Pancreatic cancer" applicable to this article?

Thanks for your feedback.